Clinical and Radiological Evaluation of Severity of Acute Ischemic Stroke with Special Reference to Neuroinflammatory Biomarkers
Klinische und radiologische Bewertung der Schwere des akuten ischämischen Schlaganfalls mit besonderem Bezug auf neuroinflammatorische Biomarker
Annals of African Medicine · 2025-07 · 24 (3) · 567-572
DOI: 10.4103/aam.aam_78_24 ↗Auf einen Blick
Bei 75 Patient:innen mit akutem ischämischem Schlaganfall waren MMP-9, IL-6, S100B und hs-CRP mit der klinischen Schwere assoziiert. Höhere Werte fanden sich in schwereren NIHSS-Gruppen.
Fragestellung
Wie hängen neuroinflammatorische Biomarker mit der Schwere und dem Verlauf eines akuten ischämischen Schlaganfalls zusammen?
Methode
18-monatige Studie mit 75 Patient:innen mit akutem ischämischem Schlaganfall; NIHSS zur Schwerebeurteilung; MMP-9, hs-CRP, IL-6 und S100B per ELISA.
Ergebnisse
MMP-9, IL-6 und S100B waren signifikant mit der Schlaganfallschwere assoziiert: IL-6 χ2=24,69 (P=0,00), S100B χ2=11,91 (P=0,008), MMP-9 χ2=19,5 (P=0,00). Die Mittelwerte waren in schwereren Gruppen erhöht.
Schlussfolgerung der Autor:innen
Neuroinflammatorische Marker wie MMP-9, IL-6, S100B und hs-CRP sind laut Autor:innen vielversprechende Biomarker zur Diagnostik und klinischen Beurteilung im akuten Stadium und haben starke unabhängige Vorhersagewerte für das Schlaganfalloutcome.
Kernaussagen
- MMP-9, IL-6 und S100B waren mit der NIHSS-Schwere assoziiert
- Höhere Biomarkerwerte fanden sich bei schwereren Schlaganfällen
- Autor:innen sehen Potenzial für Diagnostik und Outcome-Prognose
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Fachartikel in der Zeitschrift Annals of African Medicine, online erschienen am 01.04.2025. Verfasst von K C Shashidhara und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Medicine, JSS Medical College and Hospital, JSSAHER, Mysuru, Karnataka, India. Hauptthemen laut MEDLINE: Ischemic Stroke, Inflammation, Brain Ischemia, Stroke. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-SA 4.0).
Themen: Schlaganfall
Abstract (Originalsprache)
Background
Given the complexity of stroke, diverse mechanisms are known to be involved in its pathophysiology among which inflammation is one of the major culprits. Poor clinical outcomes are seen in those stroke patients with significant systemic inflammation. Therapeutic options to fight stroke are still limited and the only approved drug is tissue-plasminogen activator and/or mechanical thrombectomy. As inflammation highly influences susceptibility of stroke patients to overcome the disease, there is an increasing need to develop new diagnostic, prognostic, and therapeutic strategies for poststroke inflammation. Subjects and Methods: This study was conducted over a period of 18 months. Seventy-five patients who were diagnosed with acute ischemic stroke based on patient’s clinical history, neurological signs, and radioimaging were included. Patients underwent computed tomography scan/magnetic resonance imaging scan within 24 h of admission to exclude stroke mimics and primary intracerebral hemorrhage. National Institutes of Health Stroke Scale (NIHSS) was used to assess the severity of stroke clinically. Inflammatory biomarkers such as plasma MMP-9, high-sensitivity C-reactive protein (hs-CRP), interleukin-6 (IL-6), and S100B were measured using the ELISA kits.
Results
We observed that plasma concentration of MMP-9, IL-6, and S100B showed statistical significant association with severity of stroke as assessed by NIHSS, with Chi-square test values of χ 2 = 24.69 for IL-6 ( P = 0.00), χ 2 = 11.91 for S100B ( P = 0.008), and χ 2 = 19.5 for MMP-9 ( P = 0.00). The mean values of MMP-9, IL-6, S100B levels, and hs-CRP levels were significantly elevated in severe, moderately to severe stroke groups as related with mild stroke group as evaluated by NIHSS.
Conclusion
Neuroinflammatory markers such as MMP-9, IL-6, S100B, and hs-CRP are the promising tool as inflammatory biomarkers with other indicators of acute ischemic injury to diagnose acute ischemic stroke and facilitate a better clinical assessment of patients during the acute phase of the disease. More importantly, this study showed that these biomarkers have strong independent prediction values for stroke outcome. We propose that some of those biomarkers might turn out to be targets to be therapeutically altered overcoming the urgent need for the identification of potent drugs to modulate stroke-associated inflammation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of General Medicine, JSS Medical College and Hospital, JSSAHER, Mysuru, Karnataka, India.
- Department of General Medicine, CMC Vellore, Tamil Nadu, India.
Zitieren
APA
Shashidhara, K. C., Padamati, A. R., Manthappa, M., & Prasad, M. C. (2025). Clinical and Radiological Evaluation of Severity of Acute Ischemic Stroke with Special Reference to Neuroinflammatory Biomarkers. Annals of African Medicine, 24(3), 567-572. https://doi.org/10.4103/aam.aam_78_24
Vancouver
Shashidhara KC, Padamati AR, Manthappa M, Prasad MC. Clinical and Radiological Evaluation of Severity of Acute Ischemic Stroke with Special Reference to Neuroinflammatory Biomarkers. Annals of African Medicine. 2025;24(3):567-572. doi:10.4103/aam.aam_78_24
BibTeX
@article{Shashidhara2025,
author = {Shashidhara, K C and Padamati, Ashika Reddy and Manthappa, M and Prasad, M C},
title = {Clinical and Radiological Evaluation of Severity of Acute Ischemic Stroke with Special Reference to Neuroinflammatory Biomarkers},
journal = {Annals of African Medicine},
year = {2025},
volume = {24},
number = {3},
pages = {567--572},
doi = {10.4103/aam.aam_78_24}
}
EUVIMED